Mark Hurtt, M.D. is Interim Chief Medical Officer of Castle Creek Biosciences. He has been a clinical research consultant to biotechnology companies for more than a decade, focusing on clinical and regulatory strategies for the approval of cell and gene therapies for rare and ultra-rare diseases. Before practicing as a consultant, he was Chief Medical Officer at Alseres Pharmaceuticals and held positions of increasing responsibility at Neurogen Corporation and Pfizer. He earned an M.D. from Jefferson Medical College, completed an internship at Thomas Jefferson University Hospital and served as a medical officer in the United States Navy. Dr. Hurtt trained in neurology and neuropathology at the University of Pittsburgh and joined the faculty there after completion of his training. Dr. Hurtt is board-certified by the American Board of Psychiatry and Neurology and by the American Board of Pathology.
